Global and China Hormone Replacement Therapy Market Insights, Forecast to 2027

Hormone replacement therapy refers to the treatment of the patients with hormone deficiency due to conditions such as dwarfism or women nearing menopause, which requires replacement of hormones in the body whose levels have become low.
Market competition is intense. Eli Lilly, Pfizer, AbbVie, Novo Nordisk, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. Top 5 players combined 45.13% market share in all.

Market Analysis and Insights: Global and China Hormone Replacement Therapy Market
This report focuses on global and China Hormone Replacement Therapy market.
In 2020, the global Hormone Replacement Therapy market size was US$ 16210 million and it is expected to reach US$ 17990 million by the end of 2027, with a CAGR of 1.5% during 2021-2027. In China the Hormone Replacement Therapy market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.

Global Hormone Replacement Therapy Scope and Market Size
Hormone Replacement Therapy market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Hormone Replacement Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For China market, this report focuses on the Hormone Replacement Therapy market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in China.

Segment by Type
Estrogen Hormone
Growth Hormone
Thyroid Hormone
Testosterone Hormone
The proportion of estrogen hormone in 2018 is about 50%, and the proportion is in increasing trend from 2014 to 2018.

Segment by Application
Menopause
Hypothyroidism
Growth Hormone Deficiency
Male Hypogonadism
Other Diseases
The most proportion of hormone replacement therapy is used in menopause, and the proportion in 2018 is 46.2%.

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
Eli Lilly
Pfizer
AbbVie
Novo Nordisk
Merck KGaA
Mylan
Bayer
Teva
Novartis
Abbott
Roche
Endo International
Ipsen
ANI Pharmaceuticals
TherapeuticsMD